AbL Diagnostics SA (ABLD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AbL Diagnostics SA (ABLD) has a cash flow conversion efficiency ratio of 0.069x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€479.46K ≈ $560.54K USD) by net assets (€6.93 Million ≈ $8.10 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see AbL Diagnostics SA market cap and net worth for the company's overall valuation and market capitalisation.
AbL Diagnostics SA - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how AbL Diagnostics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
AbL Diagnostics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AbL Diagnostics SA ranked by their cash flow conversion efficiency. Explore AbL Diagnostics SA earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shriro Holdings Ltd
AU:SHM
|
0.205x |
|
Augwind Energy Tech Storage Ltd
TA:AUGN
|
-0.081x |
|
Rosebank Industries PLC
LSE:ROSE
|
0.000x |
|
Bizim Toptan Satis Magazalari AS
IS:BIZIM
|
1.182x |
|
Derluks Yatirim Holding AS
IS:DERHL
|
0.123x |
|
Song Ho Industrial Co Ltd
TWO:5016
|
0.013x |
|
LAVA THERAP. B.V. EO-12
F:4PKB
|
N/A |
|
Kinatico Ltd
AU:KYP
|
0.084x |
Annual Cash Flow Conversion Efficiency for AbL Diagnostics SA (2017–2025)
The table below shows the annual cash flow conversion efficiency of AbL Diagnostics SA from 2017 to 2025. View AbL Diagnostics SA (ABLD) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €7.63 Million ≈ $8.92 Million |
€1.51 Million ≈ $1.76 Million |
0.198x | +209.34% |
| 2024-12-31 | €7.49 Million ≈ $8.75 Million |
€-1.35 Million ≈ $-1.58 Million |
-0.181x | -231.96% |
| 2023-12-31 | €6.77 Million ≈ $7.91 Million |
€926.43K ≈ $1.08 Million |
0.137x | +1804.30% |
| 2022-12-31 | €6.75 Million ≈ $7.90 Million |
€-54.25K ≈ $-63.42K |
-0.008x | +62.89% |
| 2021-12-31 | €2.62 Million ≈ $3.06 Million |
€-56.69K ≈ $-66.28K |
-0.022x | -273.21% |
| 2020-12-31 | €2.36 Million ≈ $2.76 Million |
€29.51K ≈ $34.50K |
0.012x | +131.83% |
| 2019-12-31 | €7.09 Million ≈ $8.29 Million |
€-278.40K ≈ $-325.48K |
-0.039x | -446.32% |
| 2018-12-31 | €7.15 Million ≈ $8.36 Million |
€81.10K ≈ $94.82K |
0.011x | -87.62% |
| 2017-12-31 | €7.37 Million ≈ $8.62 Million |
€675.20K ≈ $789.38K |
0.092x | -- |
About AbL Diagnostics SA
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S… Read more